ÂÜÀòÂÒÂ×

Jesper Wiklund joins Klaria from New York based Oberland Capital, a health care focused private investment firm with over $1.2 billion in capital commitments where he served as Managing Director, Europe. Prior to that, he was CEO of InDex Pharmaceuticals Holding AB, a drug development company listed on NASDAQ First North and based in Stockholm, Sweden. Over the course of his 20+ year career in the life science industry, Jesper Wiklund has completed strategic transactions with an aggregate value exceeding $1 billion and he has raised four rounds of Venture Capital from top-tier European Investors. He was born in 1969, holds an MBA from Harvard Business School and a Bachelor of Science in Biology from St. Mary’s College of California. Jesper Wiklund owns 1 203 654 shares in Klaria Pharma.